MRKR:NASDAQMarker Therapeutics, Inc. Analysis

Marker Therapeutics is trading at $1.57, just above its calculated support of $1.37 and shy of the $1.60 resistance, with the 20‑day SMA ($1.45) virtually flat against the 50‑day SMA ($1.46), indicating a neutral price trend. The RSI sits at 61, suggesting modest upward momentum without being overbought, while the MACD line is bullish (+0.0025) and the histogram remains positive, reinforcing a short‑term bias toward price appreciation. Volatility is elevated at 48% over the past 30 days and beta exceeds 1.2, pointing to a stock that moves sharply with market swings. The valuation metrics are striking: a price‑to‑book of 1.9 and a price‑to‑sales of over 7, combined with a negative PE and a forward PE of –9.2, imply the market is pricing in significant risk but also leaves room for upside, as reflected by the 401% upside/downside estimate and an “Extreme Greed” sentiment reading. Liquidity appears stable with average volumes around 90k shares, yet the market cap is only $26 M, underscoring the thinness of the float.
Fundamentally, MRKR is a cash‑rich, debt‑free biotech with $14.9 M in cash and no debt, but it is burning cash – operating cash flow is –$7.9 M and free cash flow –$5.2 M – and has no revenue growth, negative margins, and a ROE of –77%. The pipeline centers on early‑stage T‑cell therapies (MT‑601, MT‑401‑OTS) still in Phase 1, meaning clinical‑trial risk dominates the outlook. Analyst consensus is a strong‑buy with a mean target price near $8, suggesting a perceived upside of roughly fivefold, but the lack of earnings, high cash burn, and sector‑specific regulatory uncertainty temper that enthusiasm.